"Keystone Clinical Studies is a dedicated clinical trial site focused on finding new treatments for Alzheimer’s disease and other psychiatric disorders by bridging the gap between science and clinical practice. We strive to improve the lives of individuals, families, and communities through the development of new medications for the treatment of neuropsychiatric disorders."

During the past decade, Keystone Clinical Studies, LLC conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 7 clinical trials were completed, i.e. on average, 30.4% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 5 clinical trials were completed. i.e. 35.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Keystone Clinical Studies, LLC" #1 sponsor was "Cephalon" with 4 trials, followed by "Sunovion" with 4 trials sponsored, "Athira Pharma" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Keystone Clinical Studies, LLC" #1 collaborator was "Biogen" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Alzheimer's Clinical Trials Consortium" with 1 trials as a collaborator, "Alzheimer's Disease Cooperative Study (ADCS)" with 1 trials as a collaborator and "National Institute on Aging (NIA)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Keystone Clinical Studies, LLC" are "Alzheimer Disease" (8 trials), "Depressive Disorder, Major" (5 trials), "Schizophrenia" (5 trials), "Adult Attention Deficit Hyperactivity Disorder" (2 trials) and "Alzheimer's Disease" (2 trials). Many other conditions were trialed in "Keystone Clinical Studies, LLC" in a lesser frequency.

Most popular intervention types in "Keystone Clinical Studies, LLC" are "Drug" (36 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "ATH-1017" (3 trials), "Rapastinel" (3 trials), "Aticaprant" (2 trials) and "BMS-820836" (2 trials). Other intervention names were less common.

The vast majority of trials in "Keystone Clinical Studies, LLC" are 36 trials for "All" genders.

Currently, there are NaN active trials in "Keystone Clinical Studies, LLC". undefined are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Keystone Clinical Studies, LLC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Keystone Clinical Studies, LLC, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".